Robert Hariri, M.D., Ph.D., is an engineer, a jet aviator, a movie producer, a professor and a surgeon. However, it’s his experience as a biomedical scientist that led to him to be a successful serial entrepreneur, including his most recent biopharma venture — Celularity Therapeutics.
When I look at the state of the contract manufacturing and development industry, I see an industry ripe for disruption. It isn’t inconceivable to envision an outsider coming in to shake things up.
While some might think Orchard’s whirlwind rise to be a bit of luck and good timing, the reality is it involved an extremely well-executed plan — and maybe a small dose of good fortune.
Liz Barrett recently sat down with Life Science Leader to share some of the formative experiences that shaped her into the leader she has become, including one of the most recent challenges she is embracing at Novartis.
An inside look into how this fledgling biopharma has raised over $150 million and enlisted two high-profile CEOs from one of the hottest VC firms around, all in less than two years.
In last’s year’s manufacturing outlook we delved into biopharma’s manufacturing capacity crunch. While lack of manufacturing capacity remains a challenge for the industry, the future of biopharma manufacturing has never looked so bright, and there are a variety of reasons why.
Today we stand on the precipice overlooking a new frontier — the century of biology, and businesses of all kinds need to be prepared to not only embrace what is coming, but have a strategy for how to leverage biology for the betterment of their businesses and the good of the planet.
During Kite Pharma’s (NASDAQ: KITE) company presentation at the February 2015 BIO CEO Investor’s Conference in New York, Arie Belldegrun, M.D., created a noticeable buzz among attendees when touting the latest developments coming out of the company he founded back in 2009.